Paper Details

  1. Home
  2. Paper Details

Drug Sensitivity of Vaccine-Derived Rubella Viruses and Quasispecies Evolution in Granulomatous Lesions of Two Ataxia-Telangiectasia Patients Treated with Nitazoxanide.

Author: DorseyMorna, FaisthalabRaeesa, IcenogleJoseph, PerelyginaLudmila, SullivanKathleen E, SuppiahSuganthi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Rubella virus (RuV) can cause chronic granulomas in individuals with inborn errors of immunity. This study investigated the effectiveness of nitazoxanide (NTZ) treatment for RuV-associated granulomas. Although NTZ reduced RuV RNA in skin lesions, it did not effectively eliminate live virus. This suggests that treatment failures may be due to low sensitivities of the virus to NTZ.
Paper Details　
Original Abstract of the Article :
A strong association between rubella virus (RuV) and chronic granulomas, in individuals with inborn errors of immunity, has been recently established. Both the RA27/3 vaccine and wild-type RuV strains were highly sensitive to a broad-spectrum antiviral drug, nitazoxanide (NTZ), in vitro. However, NT...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955873/

データ提供：米国国立医学図書館（NLM）

Drug Sensitivity of Vaccine-Derived Rubella Viruses: Insights from Ataxia-Telangiectasia Patients

The field of [virology] is constantly striving to understand the complex interactions between viruses and the immune system. This study investigates the [drug sensitivity] of [vaccine-derived rubella viruses (iVDRVs)] in patients with [ataxia-telangiectasia]. The authors analyzed data from two patients with ataxia-telangiectasia who were treated with [nitazoxanide (NTZ)]. The study examines the effectiveness of NTZ against iVDRVs and explores the potential for [quasispecies evolution] during treatment.

NTZ and iVDRVs: Understanding Drug Sensitivity and Resistance

This study highlights the challenges of treating iVDRVs in patients with ataxia-telangiectasia. The researchers found that while NTZ showed in vitro activity against both [RA27/3 vaccine] and [wild-type RuV strains], it was less effective against iVDRVs. Furthermore, the study suggests that long-term NTZ treatment did not lead to the emergence of resistance, but rather, the low sensitivity of iVDRVs to the drug likely contributed to treatment failures.

Navigating iVDRV Infections: A Complex Challenge

This study provides valuable insights into the challenges of treating iVDRV infections in individuals with ataxia-telangiectasia. The findings highlight the need for careful consideration of drug sensitivity and potential limitations of current antiviral therapies. Further research is needed to develop more effective treatment strategies for iVDRV infections in immunocompromised patients.

Dr.Camel's Conclusion

This study sheds light on the complex interactions between viruses and the immune system, particularly in the context of iVDRV infections in ataxia-telangiectasia patients. The findings highlight the challenges of treating these infections and underscore the importance of further research to develop more effective antiviral therapies.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-03-29
Further Info :

Pubmed ID

35335662

DOI: Digital Object Identifier

PMC8955873

Related Literature

Article Analysis
・Causes of rubella
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.